A Phase 2 interventional study of Melatonin in Diabetic Peripheral Neuropathy, Diabetic Neuropathy and Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Ain Shams University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetic Neuropathies with a site in Egypt — 9 open to participants now, 9 under way, none of them phase 3. Diabetic Neuropathies · Egypt.
Among the 31 studies in Diabetic Neuropathies with a site in Egypt, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 2, and was the 26th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →9 of the 31 studies in Diabetic Neuropathies with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 45–60
Ain Shams University · Sites in Egypt
Ages 45+
Cairo University · Sites in Egypt
Ages 18–70
South Valley University · Sites in Egypt
Ages 40–60
Sohag University · Sites in Egypt
Ages 33–65
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 3
First in 2015; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 60 across the 22 interventional studies, 65 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 31 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 3 studies filed under Diabetic Neuropathies — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Neuropathies with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07306884Assiut UniversityNeurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy | 2027-01 |
| NCT07036796Ain Shams UniversityEffect of Melatonin in Patients With Diabetic Peripheral Neuropathy | 2027-07-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetic Neuropathies with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.
Diabetic neuropathy is a microvascular complication affecting 50% of patients throughout their lifetime. It leads to various complications including foot ulcerations and lower limb amputations, thus impairs the patient's quality of life. Distal symmetrical polyneuropathy is the most common subtype. Symptoms include tingling, burning and electrical pain associated with nocturnal exacerbation. Almost 50% of patients are asymptomatic thus diagnosis must include assessment of signs.
Pathophysiologic mechanism behind hyperglycemia induced nerve damage include the activation of various pathways including polyol and advanced glycation end product (AGE), which produces reactive oxygen species. Molecular studies have revealed the involvement of certain transcriptional regulators such as Nrf2-Keap1 and NfKb inflammatory cascade.
Nuclear erythroid growth factor-2 (Nrf2) functions primarily as a defense mechanism in cellular oxidative stress, producing anti-oxidant enzymes as glutathione reductase (GSH) and superoxide dismutase (SOD). However, in long term hyperglycemia, downregulation of nrf2 takes place, leading to accumulation of reactive oxygen species (ROS), which in turn activates nfkb inflammatory pathway and produces various cytokines such as tumor necrosis factor-alpha (Tnf-alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6). Tumor-necrosis factor is known to be highly associated with nerve damage.
Drugs that target disease pathophysiology are currently unavailable, instead DPN management mainly depends on lifestyle modification through weight loss, blood pressure, blood glucose, lipid profile management along with symptomatic care. Yet these fail to stop disease progression.
Melatonin is known to possess anti-oxidant and anti-inflammatory properties through upregulating nrf2. It's hypothesized that adding it to standard therapy shall activate nrf2, and downregulate nfkb pathway and inflammatory cytokines, improving disease progression and patient's quality of life.
The aim of the current study is to measure the effect of melatonin on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with DPN.
All patients will be assessed for the following data at baseline:
Lab assessment will be done at both baseline and at the end of the trial to assess the effect of melatonin on the following:
Assessment of clinical outcomes will be done as well, at both baseline and endpoint using the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1: Melatonin group (n=30) Patients will receive 10 mg (2 5mg Capsules) 1 hour before bedtime for 12 weeks, in addition to the standard therapy.
Drug: Melatonin
Group 2: No intervention, (n=30) patients will receive only standard therapy for 12 weeks
Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway. Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice.
Concentration of human nuclear factor erythroid 2-related factor (Nrf2)
Oxidative stress marker
Time frame: Change from baseline human Nuclear factor erythroid 2-related factor at 3 months.
Concentration of Tumor necrosis factor alpha
Inflammatory marker
Time frame: Change from baseline Tumor necrosis factor alpha at 3 months
Michigan neuropathy screening instrument questionnaire (MNSI-Q)
A questionnaire of 15 yes or no questions, a score of 7 or more means more neuropathic symptoms
Time frame: At baseline and after 3 months
Toronto clinical scoring system (TCSS)
A scoring system used to assess symptoms, reflexes and signs, as score increases indicates more neuropathy.
Time frame: At baseline and after 3 months
Diabetic neuropathy score (DNS)
A score used to assess the major symptoms of DPN.
Time frame: At baseline and after 3 months
D-39 questionnaire
A questionnaire used to test the effect of diabetes on patient's quality of life.
Time frame: At baseline and after 3 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin